한글목차

DEXTENZA는 눈꺼풀의 천연 개구인 점비에서 안구에 삽입되는 코르티코 스테로이드의 안구 삽입제이며, 방부제를 사용하지 않고 덱사메타손을 최대 30 일 동안 눈 표면에 전달하도록 설계되었습니다. 치료 후 DEXTENZA는 재 흡수되어 코 눈물 시스템에서 배출됩니다.

DEXTENZA는 눈꺼풀의 코 쪽에서 코 눈물관에 삽입하는 점안제입니다. DEXTENZA는 1회 0.4mg의 덱사메타손을 삽입 후 30일간 방출합니다. 덱사메타손은 여러 염증성 사이토카인을 억제하여 염증을 억제하고 부종, 피브린 침착, 모세 혈관 누출, 염증 세포의 이동을 감소시키는 것으로 나타났습니다.

본 보고서는 주요 7개국에서 DEXTENZ 시장에 대해 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술 후 통증에서 DEXTENZA 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 DEXTENZA 시장 평가

• 수술 후 통증에서 DEXTENZA 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"DEXTENZA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about DEXTENZA for Postoperative pain in the seven major markets. A detailed picture of the DEXTENZA for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DEXTENZA for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DEXTENZA market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eyelid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA resorbs and exits the nasolacrimal system without needing removal.

Dosage and administration

DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum and into the canaliculus. A single DEXTENZA releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion.

Mechanism of action

Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DEXTENZA description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on DEXTENZA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DEXTENZA research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around DEXTENZA.
• The report contains forecasted sales of DEXTENZA for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for DEXTENZA in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DEXTENZA Analytical Perspective by DelveInsight

• In-depth DEXTENZA Market Assessment

This report provides a detailed market assessment of DEXTENZA for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• DEXTENZA Clinical Assessment

The report provides the clinical trials information of DEXTENZA for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DEXTENZA dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to DEXTENZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DEXTENZA in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of DEXTENZA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DEXTENZA in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of DEXTENZA?
• What is the clinical trial status of the study related to DEXTENZA in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DEXTENZA development?
• What are the key designations that have been granted to DEXTENZA for Postoperative pain?
• What is the forecasted market scenario of DEXTENZA for Postoperative pain?
• What are the forecasted sales of DEXTENZA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to DEXTENZA for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. DEXTENZA Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DEXTENZA Market Assessment

• 5.1. Market Outlook of DEXTENZA in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DEXTENZA in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DEXTENZA in the United States for Postoperative pain
  • 5.3.2. Market Size of DEXTENZA in Germany for Postoperative pain
  • 5.3.3. Market Size of DEXTENZA in France for Postoperative pain
  • 5.3.4. Market Size of DEXTENZA in Italy for Postoperative pain
  • 5.3.5. Market Size of DEXTENZA in Spain for Postoperative pain
  • 5.3.6. Market Size of DEXTENZA in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of DEXTENZA in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options